Induction immunosuppression in liver transplantation: a review.
Published
Journal Article (Review)
Antibody therapy for induction is seldom used in liver transplantation in the United States, but continues to be used in approximately 10% of patients. The most commonly used antibody at the current time is basiliximab (Simulect, Novartis) and is used in adults with renal dysfunction at the time of liver transplantation with the intention of delaying introduction of calcineurin-inhibitors. In children, the same antibody is commonly used in order to reduce rates of acute rejection. Most patients, adult and pediatric, are treated with initially higher levels of tacrolimus rather than antibody induction.
Full Text
Duke Authors
Cited Authors
- Turner, AP; Knechtle, SJ
Published Date
- July 2013
Published In
Volume / Issue
- 26 / 7
Start / End Page
- 673 - 683
PubMed ID
- 23651083
Pubmed Central ID
- 23651083
Electronic International Standard Serial Number (EISSN)
- 1432-2277
Digital Object Identifier (DOI)
- 10.1111/tri.12100
Language
- eng
Conference Location
- England